
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in TYK Medicines, Inc (浙江同源康醫藥股份有限公司), you should at once hand this circular and the accompanying form(s) of proxy to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



TYK Medicines, Inc
浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2410)

(1) RE-ELECTION OF THE RETIRING DIRECTORS;
(2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION;
AND
(3) NOTICE OF THE SECOND EXTRAORDINARY
GENERAL MEETING OF 2026

Capitalized terms used in this cover page shall have the same meanings as defined in this circular. A letter from the Board is set out on pages 3 to 8 of this circular.

The Company will convene and hold the EGM on 8th Floor, Building T2, China Eastern Binjiang Center, No. 277 Longlan Road, Xuhui District, Shanghai, the PRC at 2:00 p.m. on Friday, October 16, 2026. The notice of the EGM is set out on pages EGM-1 to EGM-3 of this circular. The proxy form for use at the EGM is enclosed herein, which was also published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.tykmedicines.com).

Whether or not you intend to attend and/or vote at the EGM in person, you are requested to complete the proxy form in accordance with the instructions printed thereon and return the proxy form to the H Share registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible and in any event, not later than 24 hours before the time appointed for holding the EGM (i.e. 2:00 p.m. on Thursday, October 15, 2026) or any adjournment thereof (as the case may be). Completion and return of the proxy form will not preclude you from attending and voting in person at the EGM or any adjournment thereof (as the case may be) should you so wish, and in this case, the proxy form should be deemed to be revoked.

Reference to times and dates in this circular are to Hong Kong local times and dates.

September 30, 2026

TABLE OF CONTENTS

DEFINITIONS.....	1
LETTER FROM THE BOARD.....	3
APPENDIX I – BIOGRAPHICAL DETAILS OF THE RETIRING DIRECTORS PROPOSED FOR RE-ELECTION	9
APPENDIX II – PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION.....	15
NOTICE OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2026	EGM-1

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

“Articles of Association”	the articles of association of the Company, as amended from time to time
“Board” or “Board of Directors”	the board of Directors
“China” or the “PRC”	the People’s Republic of China, for the purpose of this circular only, excluding Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan, except where the context requires otherwise
“Company”, “we”, “us”, or “our”	TYK Medicines, Inc (浙江同源康醫藥股份有限公司), a joint stock company incorporated in the PRC with limited liability on November 2, 2017
“Director(s)”	the director(s) of the Company
“EGM” or “Extraordinary General Meeting”	the second extraordinary general meeting of 2026 of the Company to be convened on 8th Floor, Building T2, China Eastern Binjiang Center, No. 277 Longlan Road, Xuhui District, Shanghai, the PRC at 2:00 p.m. on Friday, October 16, 2026 or any adjournment thereof
“Group”	the Company, its subsidiaries and its consolidated affiliated entities from time to time
“H Share(s)”	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and traded in Hong Kong Dollars and listed on the Stock Exchange
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
“RMB”	Renminbi, the lawful currency of the PRC
“Share(s)”	share(s) of the Company

DEFINITIONS

“Shareholder(s)”	holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“treasury share(s)”	H Share(s) bought back and held in treasury by the Company, which has the meaning ascribed to it under the Listing Rules
“%”	per cent

LETTER FROM THE BOARD



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

Executive Director:

Dr. WU Yusheng (吳豫生)

(Chairman of the Board and Chief Executive Officer)

Non-executive Directors:

Dr. LI Jun (李鈞)

Dr. GU Eric Hong (顧虹)

Mr. HE Chao (何超)

Dr. ZHU Xiangyang (朱向陽)

Independent Non-executive Directors:

Dr. LENG Yuting (冷瑜婷)

Dr. XU Wenqing (許文青)

Dr. SHEN Xiuhua (沈秀華)

Mr. JIANG Xiaolin (江曉林)

Registered Office and Headquarter:

Room 1403-2, Floor 14, Tower A

Changxing World Trade Building

No. 1278 Mingzhu Road

Changxing Economic Development Zone

Huzhou

Zhejiang Province

PRC

Principal Place of Business in the PRC:

8th Floor, Building T2

China Eastern Binjiang Center

No. 277 Longlan Road

Xuhui District

Shanghai

PRC

Principal Place of Business in Hong Kong:

Room 1901, 19/F, Lee Garden One

33 Hysan Avenue

Causeway Bay

Hong Kong

September 30, 2026

To the Shareholders

Dear Sir/Madam,

- (1) RE-ELECTION OF THE RETIRING DIRECTORS;
(2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION;
AND
(3) NOTICE OF THE SECOND EXTRAORDINARY
GENERAL MEETING OF 2026**

LETTER FROM THE BOARD

I. INTRODUCTION

The purpose of this circular is to provide you with information regarding the resolutions to be proposed at the EGM to be held on Friday, October 16, 2026, to enable you to make an informed decision on whether to vote for or against the proposed resolutions at the EGM. For details of the resolutions to be proposed at the EGM, please refer to the notice of the EGM.

At the EGM, ordinary resolutions will be proposed to consider and, if thought fit, approve the following matters:

- (1) The re-election of the retiring Directors; and

a special resolution will be proposed to consider and, if thought fit, approve the following matter:

- (2) Proposed amendments to the Articles of Association.

II. MATTERS TO BE CONSIDERED AT THE EGM

ORDINARY RESOLUTION

(1) RE-ELECTION OF THE RETIRING DIRECTORS

Reference is made to the announcement of the Company dated August 17, 2026 in relation to, among other things, the proposed re-election of Directors.

The terms of office of certain Directors are due to expire, and the Nomination Committee of the Board (the “**Nomination Committee**”) has reviewed the re-election of the retiring Directors and made recommendations to the Board to propose the re-election of the retiring Directors for Shareholders’ approval at the EGM. The Board has resolved to recommend the re-election of the following persons as Directors, and believes that with the knowledge and experience of the retiring Directors, they will continue to make valuable contributions to the Board and enhance the diversity of skills and perspectives of the Board. Ordinary resolutions will be proposed at the Extraordinary General Meeting to consider the re-election of the retiring Directors for a term of three years (or until the expiry of the term of office of the second session of the Board), with effect from the date of approval at the EGM.

The candidates proposed for re-election at the EGM will be: (i) Dr. WU Yusheng as an executive Director; (ii) Dr. LI Jun, Dr. GU Eric Hong and Mr. HE Chao as non-executive Directors; and (iii) Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.

LETTER FROM THE BOARD

As at the date of this circular, save as disclosed in Appendix I, each of the proposed candidates has confirmed that: (i) he/she does not have any relationship with any Director, senior management, chief executive, substantial shareholder or controlling shareholder of the Company (as defined in the Listing Rules); (ii) he/she does not hold any other position within the Company and other members of the Group; (iii) he/she has not held any directorship in any other listed public companies whose shares are listed on any securities market in Hong Kong or overseas in the past three years; (iv) he/she does not have, and is not deemed to have, any interest in any Shares or underlying shares of the Company or its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)); (v) there is no other information required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, nor has he/she participated in or been involved in any activity required to be disclosed pursuant to the aforesaid rules; and (vi) there are no other matters in relation to his/her re-election that need to be brought to the attention of the Shareholders or the Stock Exchange.

Each of the independent non-executive Director candidates has confirmed separately that: (i) he/she meets all the independence criteria set out in Rules 3.13(1) to (8) of the Listing Rules; (ii) he/she has not in the past and does not at present have any financial or other interest in the business of the Company or its subsidiaries, nor does he/she have any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) at the time of re-election, there are no other factors that may affect his/her independence. The Nomination Committee has assessed and reviewed the independence of each independent non-executive Director candidate and is of the view that each independent non-executive Director candidate has met the independence requirements.

It is hereby proposed as an ordinary resolution for consideration and approval at the EGM (by way of cumulative voting). For details of the cumulative voting arrangements, please refer to the notes set out in the form of proxy for the second extraordinary general meeting of 2026. Subject to the approval by the Shareholders of the ordinary resolutions regarding the re-election of Directors at the EGM, the Company will renew the service contracts and/or letters of appointment with each of the re-elected Directors.

Biographical details of the above retiring Directors proposed for re-election at the EGM (which are required to be disclosed pursuant to the Listing Rules) are set out in Appendix I to this circular.

LETTER FROM THE BOARD

SPECIAL RESOLUTION

(2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Reference is made to the announcement of the Company dated August 17, 2026 in relation to, among other things, the proposed amendments to the Articles of Association.

Pursuant to Rule 13.51(1) of the Listing Rules, the Board proposes to make the following amendments to the existing Articles of Association, in order to, among other things, reflect the prevailing Company Law of the People's Republic of China which effected from July 1, 2024. Details of the proposed amendments to the Articles of Association are set out in Appendix II to this circular. Save for the proposed amendments to the Articles of Association set out in Appendix II to this circular, the other provisions of the Articles of Association remain unchanged. The legal advisers to the Company as to Hong Kong law and PRC law have confirmed respectively that the proposed amendments comply with the requirements of the Listing Rules and the applicable PRC laws. The Company also confirms that there are no unusual aspects in the proposed amendments for a company incorporated in the PRC and listed on the Stock Exchange.

This resolution has been considered and approved by the Board and will be proposed at the EGM for approval by the Shareholders, and it is also proposed to authorize the management of the Company and its authorized person(s) to handle subsequent related matters such as the filing of the Articles of Association, and to authorize the executive Directors to make fine-tuning amendments in accordance with the approval opinions of the market supervision and administration authority.

LETTER FROM THE BOARD

III. THE EGM

The notice convening the EGM on 8th Floor, Building T2, China Eastern Binjiang Center, No. 277 Longlan Road, Xuhui District, Shanghai, the PRC on Friday, October 16, 2026 at 2:00 p.m. is set out on pages EGM-1 to EGM-3 in this circular. In order to determine the holders of H Shares who are entitled to attend and vote at the forthcoming EGM, the H Share register of members of the Company will be closed from Tuesday, October 13, 2026 to Friday, October 16, 2026 (both dates inclusive), during which no H Share transfer will be registered. To be eligible to attend the EGM and vote, all completed transfer documents (accompanied by the relevant share certificates) must be submitted to the Company's H Share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, for registration before 4:30 p.m. on Monday, October 12, 2026. Pursuant to Rule 17.05A of the Listing Rules, the trustee holding unvested shares of a share scheme, whether directly or indirectly, shall abstain from voting on matters that require Shareholders' approval under the Listing Rules, unless otherwise required by law to vote in accordance with the beneficial owner's direction and such a direction is given. The trustee of the Company's share incentive scheme shall not exercise the voting rights attached to 2,060,500 Shares held by it. The record date for determining the Shareholders' eligibility to attend and vote at the EGM is Friday, October 16, 2026.

The proxy form for use at the EGM is enclosed in this circular and published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.tykmedicines.com).

If you intend to attend the EGM by proxy, you are required to return the duly completed accompanying proxy form according to the instructions printed thereon. Shareholders who intend to attend the EGM by proxy are required to duly complete the proxy form and return the same to Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong as soon as practicable but in any event not less than 24 hours before the time appointed for holding the EGM (i.e. 2:00 p.m. on Thursday, October 15, 2026), or any adjourned meeting thereof (as the case may be). Completion and return of the proxy form will not preclude you from attending and voting in person at the EGM.

LETTER FROM THE BOARD

IV. VOTING BY POLL

Pursuant to Rule 13.39(4) of the Listing Rules, any vote of Shareholders at a general meeting must be taken by poll except for purely procedural or administrative matters. The chairman of the EGM shall therefore demand that voting on the resolutions set out in the notice of the EGM be taken by way of poll pursuant to the existing Articles of Association.

V. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this supplementary circular misleading.

VI. RECOMMENDATION

The Directors consider that the proposed resolutions are in the interests of the Company and the Shareholders as a whole. As such, the Directors recommend the Shareholders to vote in favour of the resolutions set forth in the notice.

VII. MISCELLANEOUS

Your attention is drawn to the additional information set out in the appendices to this circular. Unless otherwise provided herein, the English text of this circular shall prevail over the Chinese text for the purpose of interpretation.

By order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng
Chairman, Executive Director and
Chief Executive Officer

The followings are the biographical details of the retiring Directors proposed to be re-elected at the EGM (as required by the Listing Rules):

Dr. WU Yusheng

Dr. WU Yusheng (吳豫生), aged 63, is the chairperson of the Board, our executive Director and chief executive officer. He founded the Group in November 2017, and has served as a Director and the chief executive officer of the Company since then and was re-designated as an executive Director on January 17, 2024. He is primarily responsible for overseeing the overall management, business operation, and strategies of the Group.

Dr. WU has more than 26 years of experience in biomedical research and management. He conducted research at California Institute of Technology. From July 1996 to February 2009, he worked at Schering-Plough Corporation, a pharmaceutical company principally engaged in new drug development with last position as senior principal scientist, where he was primarily responsible for novel drug discovery such as for thrombosis, obesity and Alzheimer's disease. From February 2011 to October 2017, he served as the chairman of the board of directors and chief executive officer at Tetranov Pharmaceutical, a company used to be primarily engaged in providing customized pharmaceutical intermediates synthesis services where he was primarily responsible for its overall operations. Since December 2020, Dr. WU has served as an independent non-executive Director of Shanghai Tenry Pharmaceutical Co., Ltd. (上海騰瑞製藥股份有限公司), a pharmaceutical company principally engaged in research, development and commercialization of biological drugs, covering chemical raw materials and oral solid preparations, with a focus on treatment of deep burn wound and chronic ulcer wound, where he has been primarily responsible for providing independent advice and judgment to the board of directors of the company.

In addition to roles in the Group, Dr. WU is also currently an executive Director at LeadMed (Zhejiang) Medical Technology Co., Ltd. (浙江藥領醫藥科技有限公司), an executive Director at LeadMed (Zhengzhou) Medical Technology Co., Ltd. (鄭州藥領醫藥科技有限公司) and chairman of the board of directors of Zhejiang SynthonTech Pharmaceutical Co., Ltd. (浙江雅辰藥物科技股份有限公司).

Dr. WU obtained his bachelor's degree in organic chemistry from Zhengzhou University (鄭州大學) in Henan in July 1985. Dr. WU further obtained his doctor's degree in organic chemistry from Iowa State University of Science and Technology in Iowa in December 1993. Dr. WU has also authored more than 120 scientific publications in leading chemistry and medicinal chemistry journals and has been granted more than 40 granted patents.

Dr. WU obtained various awards during his professional career, including the New Jersey Minority Award from the Plainfield and Metuchen-Edison YMCA in 2004, and the 2006 President's Award for Discovery from Schering-Plough Research Institute. Further, Dr. WU has been a "State Specially Recruited Expert" (國家特聘專家) as conferred by the Ministry of Human Resources and Social Security of the PRC (中華人民共和國人力資源和社會保障部) since 2013.

It is proposed that Dr. WU Yusheng will not receive any remuneration for serving as an executive Director. As of the date of this circular, Dr. WU Yusheng is interested in 125,041,000 H Shares through interest in controlled corporations.

Dr. LI Jun

Dr. LI Jun (李鈞), aged 63, is our non-executive Director. He joined the Group in June 2018 and served as our vice president and chief scientific officer until May 2021. He has served as a Director since January 2021. He was re-designated as a non-executive Director on January 17, 2024. He is primarily responsible for providing strategic advice on the development of the Group.

Dr. LI has over 24 years of experience in pharmaceutical research and investments. Dr. LI was a research scientist and group leader at the Institute of Materia Medica, Chinese Academy of Medical Sciences (中國醫學科學院藥物研究所), where he was involved in setting up the PRC's first doping control laboratory accredited by the International Olympic Committee. Dr. LI was a research scientist at Vion Pharmaceuticals, Inc., a biopharmaceutical company specializing in cancer treatment technologies, where he was involved in the development of the novel anti-cancer agent Triapine (currently conducting Phase III clinical trial). From September 1997, he worked for over 20 years as a principal scientist and program leader at Bristol-Myers Squibb Co., USA, a company principally engaged in the R&D and sales of pharmaceutical products, where his last position was principal scientist and where he was primarily responsible for new drug discovery, among which, one is currently undergoing Phase III clinical trial. Since June 2021, Dr. LI has been a scientific advisor engaged by HCA (Shanghai) Consulting Co., Ltd. (known as "**Morningside Ventures**" (晨興創投)).

Dr. LI obtained his bachelor's degree in applied chemistry from the University of Science and Technology of China (中國科學技術大學) in Hefei in July 1985 and his master of science from the Chinese Academy of Sciences (中國科學院) in Beijing in July 1988. Dr. LI further obtained his doctor's degree in organic chemistry from Iowa State University of Science and Technology in August 1994. Dr. LI was a post-doctoral associate at Cornell University in New York from August 1994 to July 1997.

Dr. LI co-authored over 50 peer-reviewed research papers and has been granted more than 50 U.S. or Patent Cooperation Treaty (PCT) patents. Dr. LI obtained various awards during his professional career, including the PRC “First Prize of the State Scientific and Technological Progress Award”(國家科學技術進步一等獎) from the national government of the PRC, the “Special Prize” of the China Association for Instrumental Analysis (CAIA) (中國分析測試協會特等獎獲得者), along with two “Molecule of the Year” awards and a “Chemistry Leadership Award” from Bristol Myers Squibb Co., USA.

It is proposed that Dr. LI Jun will not receive any remuneration for serving as a non-executive Director.

Dr. GU Eric Hong

Dr. GU Eric Hong (顧虹), aged 60, is our non-executive Director. He joined the Group in November 2017 and has served as a Director since then. He was re-designated as a non-executive Director on January 17, 2024. He is primarily responsible for providing strategic advice on the development of the Group.

Dr. GU has extensive experience in the pharmaceutical industry. Prior to joining the Group, he worked at Mallinckrodt Pharmaceuticals plc (formerly known as Mallinckrodt Inc.), a company engaged in R&D of drugs for autoimmune diseases and other diseases. He also worked at Zhejiang Huahai Pharmaceutical Co., Ltd. (浙江華海藥業股份有限公司) (“**Zhejiang Huahai**”), a company principally engaged in sales of active pharmaceutical ingredient (“**API**”), sales of finished drugs, technical services, and import and export.

Since December 2020, he has been a director and the general manager of Shanghai Aobo Pharmtech, Inc., Ltd. (上海奧博生物醫藥股份有限公司) (“**Shanghai Aobo**”), a company primarily engaged in the production and R&D of API. He has also been the general manager of Aobo Biotechnology Hubei Co., Ltd. (奧博生物醫藥科技湖北有限責任公司), a subsidiary of Shanghai Aobo, since September 2022 and a director of Hubei Sai’ao BioPharm Co., Ltd. (湖北賽奧生物製藥有限公司) (“**Hubei Sai’ao**”), a joint venture of Zhejiang Huahai and Shanghai Aobo, since May 2021.

Dr. GU obtained his bachelor’s degree from Fudan University (復旦大學) in Shanghai in 1987 and he further obtained his doctor’s degree in chemistry from the University of Missouri-St. Louis in Missouri in January 1996. Further, Dr. GU obtained his master’s degree in business administration from the University of Washington in Washington in July 2004. Since July 2017, he has been certified as a professor-level senior engineer in drug development by the Zhejiang Provincial Department of Human Resources and Social Security (浙江省人力資源和社會保障廳).

It is proposed that Dr. GU Eric Hong will not receive any remuneration for serving as a non-executive Director. As of the date of this circular, Dr. GU Eric Hong is interested in 8,010,000 H Shares through interest in controlled corporations.

Mr. HE Chao

Mr. HE Chao (何超), aged 45, is our non-executive Director. He joined the Group in June 2022 and has served as a Director since then. He was re-designated as a non-executive Director on January 17, 2024. He is primarily responsible for providing strategic advice on the development of the Group.

Mr. HE has approximately 12 years of experience in investment and finance. From July 2011 to April 2015, he successively served as a business director, branch general manager, and partner of Kunwu Jiuding Investment Management Co., Ltd. (昆吾九鼎投資管理有限公司), an equity investment company. He has been working at Beijing Huge Capital Management Co., Ltd. (北京融辰厚紀投資管理有限公司), an equity investment company, as the general manager since July 2015 and as an executive Director since February 2017 where he has been primarily responsible for overall strategy and development.

Mr. HE obtained his master's degree in business administration from Peking University in Beijing in June 2011.

It is proposed that Mr. HE Chao will not receive any remuneration for serving as a non-executive Director. As of the date of this circular, Mr. HE Chao is interested in 19,404,654 H Shares through interest in controlled corporations.

Dr. LENG Yuting

Dr. LENG Yuting (冷瑜婷), aged 42, is our independent non-executive Director. She was appointed as an independent non-executive Director on January 17, 2024. She is responsible for providing independent advice and judgment to the Board.

Dr. LENG has more than 13 years of experience in organic chemistry research and in management. From July 2011 to March 2012, Dr. LENG was a research secretary at the College of Chemistry at Zhengzhou University (鄭州大學化學學院). From April 2012 to September 2018, she served as a chemistry teacher and academic secretary at the College of Chemistry at Zhengzhou University (鄭州大學化學學院). From October 2018 to December 2019, Dr. LENG was a visiting scholar at Harvard Medical School and the Massachusetts General Hospital under the Visiting Scholar Program of the China Scholarship Council. From April 2012 to December 2023, Dr. LENG has been a lecturer at the College of Chemistry at Zhengzhou University (鄭州大學化學學院), where she is primarily responsible for teaching and conducting research. Since January 2024, Dr. LENG has served as an associate professor at the College of Chemistry at Zhengzhou University (鄭州大學化學學院), and has been long engaged in teaching and scientific research work.

Dr. LENG obtained her bachelor's degree of science in chemistry from Zhoukou Normal University (周口師範學院) in Henan in July 2006. She further obtained her doctor's degree in organic chemistry from Zhengzhou University (鄭州大學) in Henan in July 2011. Since December 2016, she was appointed as a postdoctoral researcher in medicinal chemistry at Zhengzhou University (鄭州大學) in Henan. Since April 2012, she has been certified as an intermediate university lecturer by the Henan Provincial Department of Human Resources and Social Security (河南省人力資源和社會保障廳). Since January 2024, Dr. LENG Yuting has been awarded the Associate Professor Qualification Certificate accredited by Zhengzhou University.

It is proposed that Dr. LENG Yuting shall receive a remuneration of RMB12,000 per month (before tax) for services as an independent non-executive Director.

Dr. XU Wenqing

Dr. XU Wenqing (許文青), aged 62, is our independent non-executive Director. He was appointed as an independent non-executive Director on January 17, 2024. He is responsible for providing independent advice and judgment to the Board.

Dr. XU has over 16 years of experience in teaching and academia. Prior to joining the Group, he conducted research for Harvard Medical School. From July 2009 to August 2019, Dr. XU was a tenured full professor at the University of Washington School of Medicine. Prior to joining the Group, he was also director of the National Facility for Protein Science in Shanghai, Chinese Academy of Sciences (中國科學院國家蛋白質科學研究(上海)設施), which was involved in launching the Protein Data Bank China, an associate member of the Worldwide Protein Data Bank which manages the 3D structure archive of proteins, nucleic acids and complex assemblies. Since August 2019, he has been a tenured full professor at Shanghai Tech University (上海科技大學).

Dr. XU obtained his doctor's degree in biology from the Massachusetts Institute of Technology in Massachusetts in September 1995. Dr. XU received the Investigator's Award in the pathogenesis of infectious disease from the Burroughs Wellcome Fund in 2003.

It is proposed that Dr. XU Wenqing shall receive a remuneration of RMB12,000 per month (before tax) for services as an independent non-executive Director.

Dr. SHEN Xiuhua

Dr. SHEN Xiuhua (沈秀華), aged 54, is our independent non-executive Director. She was appointed as an independent non-executive Director on January 17, 2024. She is responsible for providing independent advice and judgment to the Board.

Dr. SHEN has approximately 30 years of experience in teaching and academia. Since August 1995, Dr. SHEN consecutively worked as a teaching assistant in the Department of Pathology of the School of Medicine, a lecturer, an associate professor and currently a professor in the Department of Nutrition of the School of Medicine at Shanghai Jiao Tong University (上海交通大學). From September 2007 to February 2008, she was a visiting scholar at the Division of Nutritional Sciences at Cornell University. From November 2013 to October 2014, she was a visiting scholar at Harvard University.

Dr. SHEN obtained her bachelor's degree in clinical medicine (medical nutrition) and her master's degree in medicine, with a major in nutrition and food hygiene, from Shanghai Jiao Tong University (上海交通大學) in Shanghai in July 1995 and June 2001, respectively. Dr. SHEN further obtained her doctor's degree in pediatrics from Shanghai Jiao Tong University (上海交通大學) in Shanghai in July 2007.

It is proposed that Dr. SHEN Xiuhua shall receive a remuneration of RMB12,000 per month (before tax) for services as an independent non-executive Director.

Articles before amendment	Articles after amendment
Article 8 The legal representative of the Company shall be the director who executes corporate affairs on the Company's behalf. If the director who acts as the legal representative resigns, he shall be deemed to have resigned as the legal representative at the same time. If the legal representative resigns, the company shall determine a new legal representative within 30 days from the date of the legal representative's resignation. The director who executes corporate affairs is subject to election by the Board.	Article 8 The legal representative of the Company shall be the director who executes corporate affairs on the Company's behalf. If the director who acts as the legal representative resigns, he shall be deemed to have resigned as the legal representative at the same time. If the legal representative resigns, the company shall determine a new legal representative within 30 days from the date of the legal representative's resignation. The director who executes corporate affairs <u>on the Company's behalf</u> is subject to election by the Board.
Article 19 The Company has issued a total of 380,065,818 shares, all of which are ordinary shares, comprising 4,608,000 unlisted shares and 375,457,818 H Shares; and the registered capital of the Company shall be RMB380.065818 million.	Article 19 The Company has issued a total of 380,065,818 shares, all of which are ordinary shares, comprising 4,608,000 unlisted shares and 375,457,818 H Shares; and the registered capital of the Company shall be RMB380.065818 million <u>and H Shares.</u>
Article 85 The list of candidates for Director shall be proposed to the shareholders' general meeting for voting. The ways and procedures for nominating Directors of the Company are: (I) When a re-election of the Board of Directors or an additional or replacement of Director made by the Board of Directors takes place, incumbent Board of Directors and shareholders individually or collectively holding 3% or more of voting rights attached to the Company's share may nominate candidates, without exceeding the number of persons to be elected, for the position of Director for the next session of the Board of Directors or additional candidates for the position of Director; 	Article 85 The list of candidates for Director shall be proposed to the shareholders' general meeting for voting. The ways and procedures for nominating Directors of the Company are: (I) When a re-election of the Board of Directors or an additional or replacement of Director made by the Board of Directors takes place, incumbent Board of Directors and shareholders individually or collectively holding 3% <u>1%</u> or more of voting rights attached to the Company's share may nominate candidates, without exceeding the number of persons to be elected, for the position of Director for the next session of the Board of Directors or additional candidates for the position of Director;

Articles before amendment	Articles after amendment
Article 99 The term of office of the Directors is 3 years, and they are eligible for re-election upon expiry of the term. Directors are elected or replaced by the shareholders' general meeting and may be removed by the shareholders' general meeting before the expiry of the term. Any person appointed by the Board of Directors to fill up a casual vacancy or as an addition to the Board of Directors shall hold office only until the first annual shareholders' general meeting after his/her appointment, and shall then be eligible for re-election. 	Article 99 The term of office of the Directors is 3 years, and they are eligible for re-election upon expiry of the term. Directors are elected or replaced by the shareholders' general meeting and may be removed by the shareholders' general meeting before the expiry of the term. Any person appointed by the Board of Directors to fill up a casual vacancy or as an addition to the Board of Directors shall hold office only until the first annual shareholders' general meeting after his/her appointment, and shall then be eligible for re-election.
Article 109 The Board of Directors consists of 10 members, 4 of whom are independent non-executive Directors. At any time, the Board of Directors shall consist of more than 1/3 independent non-executive Directors. The Board of Directors shall have a chairperson and no vice-chairperson.	Article 109 The Board of Directors consists of 109 members, 4 of whom are independent non-executive Directors. At any time, the Board of Directors shall consist of more than 1/3 independent non-executive Directors. The Board of Directors shall have a chairperson and no vice-chairperson.

Articles before amendment	Articles after amendment
Article 127 The Board of Directors shall establish the audit committee, the nomination committee, the remuneration and appraisal committee and the scientific committee. The Audit Committee exercises the powers and functions of the supervisory committee as stipulated in the Company Law. The Board of Directors may set up other special committees with the consent of the shareholders' general meeting. Special committees shall be accountable to the Board of Directors and perform their duties in accordance with the Articles of Association and the authorization of the Board of Directors, and their proposals shall be submitted to the Board of Directors for deliberation. The members of special committees shall consist totally of Directors. The special committee shall not pass any resolution in the name of the Board of Directors, but may exercise its decision-making power in respect of authorized matters under the special authorization of the Board of Directors, provided that it does not contravene the mandatory provisions of the relevant PRC laws, regulations, regulatory documents and the listing rules of the stock exchange where the Company's shares are listed. The Board of Directors is responsible for formulating the working rules for special committees and regulating the operation of special committees.	Article 127 The Board of Directors shall establish the audit committee, the nomination committee, the remuneration and appraisal committee and the scientific committee. The Audit Committee exercises the powers and functions of the supervisory committee as stipulated in the Company Law. <u>The scientific committee shall be responsible for regularly reviewing the strategic direction and investment in research and development and technology and making recommendations to the Board of Directors.</u> The Board of Directors may set up other special committees with the consent of the shareholders' general meeting. Special committees shall be accountable to the Board of Directors and perform their duties in accordance with the Articles of Association and the authorization of the Board of Directors, and their proposals shall be submitted to the Board of Directors for deliberation. The members of special committees shall consist totally of Directors. The special committee shall not pass any resolution in the name of the Board of Directors, but may exercise its decision-making power in respect of authorized matters under the special authorization of the Board of Directors, provided that it does not contravene the mandatory provisions of the relevant PRC laws, regulations, regulatory documents and the listing rules of the stock exchange where the Company's shares are listed. The Board of Directors is responsible for formulating the working rules for special committees and regulating the operation of special committees.

Articles before amendment	Articles after amendment
Article 129 The Audit Committee shall be responsible for examination and approval of the financial information of the Company and the disclosure thereof, as well as supervision and evaluation of internal and external audit and internal control. The following matters shall be submitted to the Board of Directors for review and consideration after obtaining the consent of more than half of the members of the Audit Committee: (1) disclosure of the financial information in financial and accounting reports and regular reports; (2) appointment or dismissal of an accounting firm which undertakes audit work of the listed company; (3) appointment or dismissal of the person-in-charge of finance of the listed company; (4) changes in accounting policies or accounting estimates or correction of significant accounting errors for reasons other than changes in accounting standards; (5) other matters as required by laws, administrative regulations, the regulations of CSRC and the Articles of Association.	Article 129 <u>The Audit Committee shall notify all members three days prior to the meeting by mail, fax or telephone (if there is an urgent need to convene a meeting in time, the notification time limit shall not be subject to the above restriction, but the notification shall be made in advance within a reasonable period of time).</u> The Audit Committee shall be responsible for examination and approval of the financial information of the Company and the disclosure thereof, as well as supervision and evaluation of internal and external audit and internal control. The following matters shall be submitted to the Board of Directors for review and consideration after obtaining the consent of more than half of the members of the Audit Committee: (1) disclosure of the financial information in financial and accounting reports and regular reports; (2) appointment or dismissal of an accounting firm which undertakes audit work of the listed company; (3) appointment or dismissal of the person-in-charge of finance of the listed company; (4) changes in accounting policies or accounting estimates or correction of significant accounting errors for reasons other than changes in accounting standards; (5) other matters as required by laws, administrative regulations, the regulations of CSRC and the Articles of Association.

Articles before amendment	Articles after amendment
Article 183 Definition (1) Unless the context otherwise requires, in the Articles of Association, the term “accounting firm(s)” has/have the same meaning as the term “auditor(s)” under the Hong Kong Listing Rules. (2) A “controlling shareholder” shall refer to the shareholders holding shares representing more than 50% of the total capital of the Company; holding less than 50 % of shares in the Company, but the voting rights vested by the shares held by him/her have a material effect on any resolutions made at a shareholders’ general meeting. Where the definition of controlling shareholder is otherwise provided in the Hong Kong Listing Rules, such provisions shall prevail. 	Article 183 Definition (1) Unless the context otherwise requires, in the Articles of Association, the term “accounting firm(s)” has/have the same meaning as the term “auditor(s)” under the Hong Kong Listing Rules. (2) A “controlling shareholder” shall refer to the shareholders holding shares representing more than 50% of the total capital of the Company; holding less than 50 % of shares in the Company, but the voting rights vested by the shares held by him/her have a material effect on any resolutions made at a shareholders’ general meeting. Where the definition of controlling shareholder is otherwise provided in the Hong Kong Listing Rules; such provisions shall prevail.

NOTICE OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2026

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



TYK Medicines, Inc
浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2410)

**NOTICE OF THE SECOND EXTRAORDINARY
GENERAL MEETING OF 2026**

NOTICE IS HEREBY GIVEN THAT the second extraordinary general meeting of 2026 (the “EGM”) of TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “Company”) will be held on 8th Floor, Building T2, China Eastern Binjiang Center, No. 277 Longlan Road, Xuhui District, Shanghai, the PRC at 2:00 p.m. on Friday, October 16, 2026 for the purpose of considering and, if though fit, passing the following resolutions. Unless otherwise required, capitalized terms used in this notice shall have the same meanings as those defined in the circular of the Company dated September 30, 2026.

ORDINARY RESOLUTIONS

1. To consider and approve the re-election of non-independent Directors (by way of cumulative voting).
 - (a) To consider and approve the re-election of Dr. WU Yusheng as an executive Director.
 - (b) To consider and approve the re-election of Dr. LI Jun as a non-executive Director.
 - (c) To consider and approve the re-election of Dr. GU Eric Hong as a non-executive Director.
 - (d) To consider and approve the re-election of Mr. HE Chao as a non-executive Director.

NOTICE OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2026

2. To consider and approve the re-election of independent non-executive Directors (by way of cumulative voting).
 - (a) To consider and approve the re-election of Dr. LENG Yuting as an independent non-executive Director.
 - (b) To consider and approve the re-election of Dr. XU Wenqing as an independent non-executive Director.
 - (c) To consider and approve the re-election of Dr. SHEN Xiuhua as an independent non-executive Director.

SPECIAL RESOLUTION

3. To consider and approve the proposed amendments to the Articles of Association.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng
*Chairman, Executive Director and
Chief Executive Officer*

Hong Kong
September 30, 2026

NOTICE OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2026

Notes:

1. All resolutions at the EGM will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Listing Rules. The results of the poll will be published on the websites of the Company at www.tykmedicines.com and the Stock Exchange at www.hkexnews.hk after the EGM.
2. Any shareholder entitled to attend and vote at the EGM convened by the above notice is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy need not be a shareholder of the Company. If a shareholder of the Company appoints more than one proxy, such proxies shall only exercise their voting rights by a poll. For the avoidance of doubt, holders of treasury shares (if any) shall abstain from voting on the relevant treasury shares at the EGM in accordance with the requirements of the Listing Rules.
3. In order to be valid, the instrument appointing a proxy together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power of attorney or authority, must be completed and returned to the H share registrar of the Company, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, at least 24 hours before the EGM (for the purpose of EGM, i.e. before 2:00 p.m. on Thursday, October 15 2026) or any adjourned meeting thereof. Completion and return of the form of proxy will not preclude a shareholder from attending and voting in person at the EGM or any adjourned meeting thereof should he/she so wish.
4. For the purpose of determining the holders of H Shares who are entitled to attend and vote at the forthcoming EGM, the H Share register of members of the Company will be closed from Tuesday, October 13, 2026 to Friday, October 16, 2026 (both dates inclusive), during which, no transfer of H Shares will be registered. In order to be eligible to attend and vote at the EGM, all completed transfer documents (which shall be accompanied by the relevant share certificates) must be lodged with the H Share registrar of the Company, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong no later than 4:30 p.m. on Monday, October 12, 2026 for registration. Pursuant to Rule 17.05A of the Listing Rules, the trustee holding unvested shares of a share scheme, whether directly or indirectly, shall abstain from voting on matters that require Shareholders' approval under the Listing Rules, unless otherwise required by law to vote in accordance with the beneficial owner's direction and such a direction is given. The trustee of the Company's share incentive scheme shall not exercise the voting rights attached to 2,060,500 Shares held by it. The record date for determining the Shareholders' eligibility to attend and vote at the EGM is Friday, October 16, 2026.
5. Where there are joint registered holders of any share, any one of such joint holders may vote, either in person or by proxy, in respect of such shares as if he/she was solely entitled thereto, but if more than one of such joint holders are present at the EGM, whether in person or by proxy, the joint registered holder present whose name stands first on the register of members of the Company in respect of the shares shall alone be entitled to vote in respect thereof.
6. A shareholder or his/her/its proxy should produce proof of identity when attending the EGM.
7. The EGM is expected to last for no more than half a business day. Shareholders and proxies attending the meeting shall be responsible for their own travel and accommodation expenses.
8. Shareholders may contact the Company at TYK02410@tykmedicines.com for any enquiries in respect of the EGM.

As at the date of this notice, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.